Payment overview · 2025
General Payments
$1,758.79
99 reported records · 23 companies
Healthcare provider profile · identity verified
Douglas M. Lakin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SCOTTSDALE, AZ · NPI 1992783492
Verified facts
What the public records show
CMS Open Payments records show Douglas M. Lakin, M.D. received $1,758.79 in general payments during 2025 across 99 reported records.
PFIZER INC. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rexulti, Synthroid, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 459 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 459 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $241.00 | 13.7% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.56 | 13.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.77 | 10.3% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.44 | 8.4% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $131.61 | 7.5% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$127.59 | 7.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $105.88 | 6.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.04 | 4.8% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.36 | 3.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $53.58 | 3.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.26 | 2.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.64 | 2.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $39.39 | 2.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.31 | 2.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.73 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.67 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.46 | 1.9% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $24.10 | 1.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $21.86 | 1.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $21.41 | 1.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.60 | 1.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.92 | 1.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.61 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,758.79 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $203.12 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $200.85 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $165.63 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $157.54 | 15 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $131.61 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $129.28 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.42 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $96.82 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.30 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $91.30 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.04 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.04 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $77.12 | 3 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $74.71 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.36 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.72 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $49.26 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.64 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $39.39 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.73 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $33.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.46 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $29.02 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $6.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 459 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 44 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 193 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 180 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 254 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
254 | 72 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
459 | 100 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
193 | 38 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
459 | 100 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
180 | 165 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1429 | 397 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1282 | 352 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 890 | 261 |
| Amlodipine Besylate | Amlodipine Besylate | 836 | 243 |
| Pantoprazole Sodium | Pantoprazole Sodium | 758 | 239 |
| Alprazolam | Alprazolam | 630 | 174 |
| Zolpidem Tartrate | Zolpidem Tartrate | 628 | 208 |
| Losartan Potassium | Losartan Potassium | 607 | 176 |
| Tamsulosin Hcl | Tamsulosin Hcl | 542 | 165 |
| Metoprolol Succinate | Metoprolol Succinate | 536 | 147 |
| Azithromycin | Azithromycin | 482 | 337 |
| Eliquis | Apixaban | 459 | 100 |
| Simvastatin | Simvastatin | 459 | 127 |
| Escitalopram Oxalate | Escitalopram Oxalate | 451 | 124 |
| Lorazepam | Lorazepam | 447 | 113 |
| Trazodone Hcl | Trazodone Hcl | 445 | 132 |
| Hydrochlorothiazide | Hydrochlorothiazide | 425 | 118 |
| Lisinopril | Lisinopril | 402 | 121 |
| Gabapentin | Gabapentin | 388 | 109 |
| Omeprazole | Omeprazole | 344 | 111 |
| Finasteride | Finasteride | 342 | 96 |
| Prednisone | Prednisone | 336 | 204 |
| Ezetimibe | Ezetimibe | 328 | 99 |
| Tramadol Hcl | Tramadol Hcl | 323 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 315 | 92 |
| Sertraline Hcl | Sertraline Hcl | 311 | 92 |
| Clonazepam | Clonazepam | 302 | 88 |
| Furosemide | Furosemide | 301 | 111 |
| Cephalexin | Cephalexin | 290 | 194 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 285 | 86 |
| Nifedipine Er | Nifedipine | 276 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 273 | 72 |
| Allopurinol | Allopurinol | 269 | 77 |
| Metformin Hcl | Metformin Hcl | 267 | 79 |
| Synthroid | Levothyroxine Sodium | 254 | 72 |
| Oxycodone Hcl | Oxycodone Hcl | 247 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 244 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 63 |
| Diazepam | Diazepam | 237 | 70 |
| Spironolactone | Spironolactone | 223 | 76 |
| Irbesartan | Irbesartan | 213 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 208 | 48 |
| Pregabalin | Pregabalin | 200 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 199 | 55 |
| Telmisartan | Telmisartan | 198 | 47 |
| Meloxicam | Meloxicam | 195 | 84 |
| Ozempic | Semaglutide | 193 | 38 |
| Potassium Chloride | Potassium Chloride | 192 | 65 |
| Memantine Hcl | Memantine Hcl | 189 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 186 | 58 |
| Paxlovid | Nirmatrelvir/Ritonavir | 180 | 165 |
| Ipratropium Bromide | Ipratropium Bromide | 168 | 58 |
| Estradiol | Estradiol | 161 | 54 |
| Montelukast Sodium | Montelukast Sodium | 160 | 49 |
| Carvedilol | Carvedilol | 159 | 41 |
| Alendronate Sodium | Alendronate Sodium | 158 | 45 |
| Celecoxib | Celecoxib | 155 | 47 |
| Donepezil Hcl | Donepezil Hcl | 155 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 43 |
| Myrbetriq | Mirabegron | 149 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 140 | 36 |
| Metformin Hcl Er | Metformin Hcl | 139 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 34 |
| Bupropion Xl | Bupropion Hcl | 137 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 135 | 102 |
| Valacyclovir | Valacyclovir Hcl | 135 | 68 |
| Atenolol | Atenolol | 132 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 128 | 87 |
| Famotidine | Famotidine | 119 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 117 | 37 |
| Eszopiclone | Eszopiclone | 112 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 58 |
| Dutasteride | Dutasteride | 108 | 34 |
| Mirtazapine | Mirtazapine | 107 | 33 |
| Ondansetron Odt | Ondansetron | 104 | 74 |
| Sumatriptan Succinate | Sumatriptan Succinate | 96 | 19 |
| Hydrocortisone | Hydrocortisone | 94 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 30 |
| Mounjaro | Tirzepatide | 88 | 15 |
| Ramipril | Ramipril | 88 | 25 |
| Januvia | Sitagliptin Phosphate | 87 | 22 |
| Temazepam | Temazepam | 87 | 29 |
| Farxiga | Dapagliflozin Propanediol | 85 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 35 |
| Glimepiride | Glimepiride | 85 | 26 |
| Lovastatin | Lovastatin | 84 | 24 |
| Propranolol Hcl | Propranolol Hcl | 82 | 22 |
| Doxepin Hcl | Doxepin Hcl | 79 | 29 |
| Fluconazole | Fluconazole | 79 | 36 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 77 | 47 |
| Azelastine Hcl | Azelastine Hcl | 76 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 26 |
| Repatha Sureclick | Evolocumab | 74 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 71 | suppressed |
| Valsartan | Valsartan | 70 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 69 | 23 |
| Jardiance | Empagliflozin | 69 | 20 |
| Meclizine Hcl | Meclizine Hcl | 68 | 49 |
| Benazepril Hcl | Benazepril Hcl | 67 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 47 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 66 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 19 |
| Trulicity | Dulaglutide | 64 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | suppressed |
| Testosterone | Testosterone | 62 | 16 |
| Amoxicillin | Amoxicillin | 60 | 37 |
| Methylphenidate Hcl | Methylphenidate Hcl | 60 | 18 |
| Liothyronine Sodium | Liothyronine Sodium | 58 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 20 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 57 | 18 |
| Trimethoprim | Trimethoprim | 57 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 56 | 17 |
| Warfarin Sodium | Warfarin Sodium | 56 | 19 |
| Terazosin Hcl | Terazosin Hcl | 55 | 15 |
| Mupirocin | Mupirocin | 54 | 46 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 11 |
| Methylprednisolone | Methylprednisolone | 52 | 49 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 16 |
| Clonidine Hcl | Clonidine Hcl | 47 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Fentanyl | Fentanyl | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 11 |
| Acyclovir | Acyclovir | 44 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Linzess | Linaclotide | 44 | 15 |
| Topiramate | Topiramate | 44 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | 13 |
| Colchicine | Colchicine | 42 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 42 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 12 |
| Aripiprazole | Aripiprazole | 39 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Ibuprofen | Ibuprofen | 39 | 16 |
| Sotalol | Sotalol Hcl | 39 | 12 |
| Sucralfate | Sucralfate | 39 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Livalo | Pitavastatin Calcium | 37 | suppressed |
| Nadolol | Nadolol | 37 | 12 |
| Naproxen | Naproxen | 37 | 15 |
| Nystatin | Nystatin | 37 | 24 |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 15 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Verapamil Sr | Verapamil Hcl | 32 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 13 |
| Mesalamine | Mesalamine | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | 12 |
| Gemtesa | Vibegron | 29 | 16 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 29 | 29 |
| Folic Acid | Folic Acid | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 12 |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Progesterone | Progesterone, Micronized | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 18 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 25 | 13 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Xtampza Er | Oxycodone Myristate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Metronidazole | Metronidazole | 22 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 18 |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Silodosin | Silodosin | 19 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 17 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Gralise | Gabapentin | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | 13 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Nucynta | Tapentadol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 12 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Isradipine | Isradipine | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,758.79 · 99 records | PFIZER INC. | AIRSUPRA, BREZTRI, CAMZYOS, CAPLYTA, CREON, ELIQUIS, FARXIGA, Flector, GEMTESA, INCEPTIV, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, KYPHON EXPRESS II KYPHOPAK TRAY, LEQVIO, LINZESS, Leqembi, Licart, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SYNTHROID, Sunosi, TONMYA, TRELEGY ELLIPTA, Tirosint, UNITHROID, VOQUEZNA, Wegovy, Yorvipath, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error